Business Context and Reporting Period
This Form 8-K filing by Trevi Therapeutics, Inc. (TRVI) reports a corporate governance event dated March 29, 2021. The company is an emerging growth company incorporated in Delaware with principal executive offices in New Haven, Connecticut.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Principal Accounting Officer: Frank P. Muscolo will cease serving as the Company's controller and principal accounting officer effective April 12, 2021, in connection with his planned retirement in early 2022.
- Appointment of New Officer: Christopher Galletta was hired to succeed Mr. Muscolo as controller and principal accounting officer, effective April 12, 2021.
- Compensatory Arrangement: Mr. Galletta was granted an option to purchase 25,000 shares of common stock at the closing price on the grant date. The option vests 25% on the first anniversary and monthly thereafter.
Outlook, Risks, and Contingencies
Management Commentary: The transition was planned in anticipation of Mr. Muscolo's retirement. Mr. Muscolo will remain an employee until his retirement date.
Contingencies: The Company entered into a standard indemnification agreement with Mr. Galletta. Under this agreement, the Company may be required to indemnify him for expenses, including attorneys' fees, judgments, fines, and settlement amounts arising from his service to the Company.
Investor Verification Checklist
- Verify the effective date of the leadership transition (April 12, 2021).
- Review the vesting schedule for the 25,000 stock options granted to the new controller.
- Confirm the terms of the indemnification agreement filed as Exhibit 10.12 to the Form S-1.
- Monitor future filings for the official retirement date of Frank P. Muscolo.